Cytori Therapeutics is terminating half of its employees a little more than one month after the company’s late-stage cell therapy to treat scleroderma failed to achieve statistical significance for both the primary and secondary trial endpoints.
French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment, was forced to suspend testing following a patient death.
As the U.S. Congress returns from summer vacation, for the first time in years gutting Obamacare will not be the main order of business on the healthcare agenda.
Novartis CEO Joe Jimenez will step down on Feb. 1, 2018, and hand over the top leadership role of the Swiss company to drug development chief Vas Narasimhan.
The U.S. Food and Drug Administration approved Pfizer Inc.’s drug Mylotarg for certain patients with acute myeloid leukemia (AML), re-clearing a drug that had been pulled off the market in 2010.
Cycle for Survival, the movement to beat rare cancers, announced funding plans for the $34 million raised in 2017 by its extraordinary community. 100 percent of this record-breaking total goes to rare cancer research and clinical trials to improve how cancer is diagnosed and treated.
ImMAGE Biotherapeutics announced the company is shutting its doors and discontinuing operations.
Janssen Biotech is terminating the collaboration and license agreement with MacroGenics relating to duvortuxizumab, a CD19 x CD3 DART molecule.